Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY1251152 · 1 trial · 1 indication
To determine the MTD of BAY1251152 in subjects with advanced hematological neoplasms
To determine the RP2D of BAY1251152 based on safety, tolerability, pharmacokinetic, and pharmacodynamic data in subjects with advanced hematological neoplasms
For assessment of the safety (ECG, vital signs, clinical significant abnormal laboratory results… etc.)and tolerability of BAY 1251152 in subjects with advanced hematological neoplasms
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | Biomarker-enriched advanced hematological neoplasms |
| Arm 2 | EXPERIMENTAL | Other selected advanced hematological neoplasms |
| Name | Type | Description |
|---|---|---|
| BAY1251152 | DRUG | Weekly infusion of BAY1251152 in 21-day cycles. |
Inclusion Criteria: * Male or female patients aged ≥18 years * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and Life expectancy of at least 12 weeks * Patients are able and willing to provide bone marrow biopsies/aspirates as requested by the protocol * Patients with confi...
BAY1251152 is an investigational small molecule being developed for the treatment of hematologic neoplasms, which are cancers of the blood and bone marrow. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
BAY1251152 is being developed by Bayer AG, a multinational pharmaceutical company headquartered in Germany. Bayer's stock is traded on the over-the-counter market under the ticker symbol BAYRY.
BAY1251152 is in Phase 1 clinical development. A Phase 1 trial for advanced blood cancers has been completed, but the drug remains investigational and has not received regulatory approval for any indication.
BAY1251152 has one completed clinical trial, identified as NCT02745743, titled 'Phase I Trial of BAY1251152 for Advanced Blood Cancers.' This trial enrolled 21 participants with hematologic neoplasms and was conducted in the United States, Germany, Spain, and the United Kingdom.
BAY1251152 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial, but it has not received marketing authorization from the U.S. Food and Drug Administration or any other regulatory agency.